OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
28
Results
Show all
Save search
Copy query
Show results for
Unknown
(28)
Release Date
2021
(10)
2022
(5)
2024
(4)
2025
(3)
2023
(2)
2020
(2)
2015
(1)
2014
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Genomic reconstruction of the SARS-CoV-2 epidemic in England.
Not available
S-EPMC8674138
|
biostudies-literature
Cite
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Not available
S-EPMC8693692
|
biostudies-literature
Cite
Defining the role of common variation in the genomic and biological architecture of adult human height.
Not available
S-EPMC4250049
|
biostudies-literature
Cite
Initial Invasive or Conservative Strategy for Stable Coronary Disease.
Not available
S-EPMC7263833
|
biostudies-literature
Cite
Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease.
Not available
S-EPMC7261489
|
biostudies-literature
Cite
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Not available
S-EPMC7787219
|
biostudies-literature
Cite
Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients With Chronic Coronary Disease: Insights From the ISCHEMIA Trial.
Not available
S-EPMC10944079
|
biostudies-literature
Cite
SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.
Not available
S-EPMC7995808
|
biostudies-literature
Cite
Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial.
Not available
S-EPMC11658795
|
biostudies-literature
Cite
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets